Efficacy was also found in the combination therapy of INO with both rituximab, gemcitabine, dexamethasone, and cisplatin (R‐GDP) as well as rituximab, cyclophosphamide, vincristine, and prednisone (R‐CVP) in R/R CD22‐positive B‐cell NHL patients in a phase 1 trial (NCT01055496).89, 90. The gene discussed is CD22; the disease is B-cell non-Hodgkin lymphoma.